Abstract
Despite several recent advances in therapy in inflammatory bowel disease (IBD), 5-aminosalicylic acid (5-ASA) therapy has retained its place especially in ulcerative colitis. This consensus on 5-ASA is obtained through a modified Delphi process, and includes guiding statements and recommendations based on literature evidence (randomized trials, and observational studies), clinical practice, and expert opinion on use of 5-ASA in IBD by Indian gastroenterologists. The aim is to aid practitioners in selecting appropriate treatment strategies and facilitate optimal use of 5-ASA in patients with IBD. (Intest Res 2020;18:355-378)
Original language | English |
---|---|
Pages (from-to) | 355-378 |
Number of pages | 24 |
Journal | Intestinal Research |
Volume | 18 |
Issue number | 4 |
DOIs | |
Publication status | Published - 2020 |
All Science Journal Classification (ASJC) codes
- Gastroenterology